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Abstract: The current HIV/AIDS scenario in India is quite grim with an estimated 2.4 million people living with 
HIV/AIDS (PLHA) in 2008, just behind South Africa and Nigeria. The anti-retroviral drugs (ARVs) remain the main stay 
of global HIV/AIDS treatment. Over 30 ARVs (single and FDCs) available under six categories viz., NRTIs (nucleoside 
reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), Protease inhibitors, the new 
Fusion inhibitors, Entry inhibitors-CCR5 co-receptor antagonists and HIV integrase strand transfer inhibitors. The major 
originator companies for these ARVs are: Abbott, Boehringer Ingelheim (BI), Bristol-Myers Squibb (BMS), Gilead, 
GlaxoSmithKline (GSK), Merck, Pfizer, Roche, and Tibotec. Beginning with zidovidine in 1987, all the drugs are 
available in the developed countries. In India, about 30 ARVs are available as generics manufactured by Aurobindo, 
Hyderabad, Andhra Pradesh; Cipla Limited, Goa; Emcure Pharmaceuticals, Pune, Maharashtra; Hetero Drugs, 
Hyderabad, Andhra Pradesh; Macleods Pharmaceuticals, Daman; Matrix Laboratories, Nashik, Maharashtra; Ranbaxy, 
Sirmour, Himachal Pradesh; and Strides Arcolab, Bangalore, Karnataka. The National AIDS Control Organization 
(NACO) set up in 1992 by the Govt. of India provides free ARVs to HIV positive patients in India since 2004. The drugs 
available in India include both single drugs and FDCs covering both first line and second line ARVs. Even while there are 
claims of stabilization of the disease load, there is still huge gap of those who require ARVs as only about 150,000 PLHA 
receive the ARVs from the Govt. and other sources. Access to ARVs therefore is still a cause of serious concern ever 
since India became fully Trade Related Aspects of Intellectual Property Rights (TRIPS)-complaint in 2005. Therefore, the 
Indian pharmaceutical companies cannot make generics for those for drugs introduced post-2005 due to product patent 
regime. Other concerns include heat stable, other better formulations and second line ARVs for adults and more drugs and 
formulations for paediatric groups, that are still to be widely available in India and other developing countries. To 
examine whether strong intellectual property (IP) protection systems are to be considered important barriers for the 
limited or lack of access to ARVs, we studied the patent profile of the ARVs of the originator companies within and 
outside India. We could record 93 patents in the United States Patent & Trademark Office (USPTO). The originator 
companies have been also aggressively filing and enforcing patents in India. There have been a few efforts by companies 
like Gilead and GSK to grant licenses to generic manufacturers in developing countries, ostensibly to promote access to 
ARVs through lower (two-tier) pricing. These steps are considered as too little and too late. There is an urgent need to 
look for alternative strategies to promote access to ARVs both linked to and independent of IPRs. Patent pooling as a 
viable strategy mooted by the UNITAID should be seriously explored to promote access to ARVs. India is ideally suited 
for trying out the patent pool strategy as most of the global requirement of affordable ARV drugs for HIV/AIDS treatment 
is sourced from Indian generic companies. 
INTRODUCTION 
  India is one of the largest and most populated countries 
in the world, with over a billion inhabitants. There are 
currently an estimated 2.4 million Indians living with 
HIV/AIDS [1]. Although HIV infection emerged as late as 
1986 in India, later than it did in many other countries, the 
infection rates rose sharply throughout the 1990s. In 1987 
the Government of India launched a National AIDS Control 
Programme (NACP) to co-ordinate national responses which 
covered surveillance, blood screening, and health education 
[2]. By the end of 1987, of the 52,907 people tested, 135 
people were found to be HIV positive and 14 had AIDS.  
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Most of these initial cases had occurred through heterosexual 
sex. But at the end of the 1980s a rapid spread of HIV was 
observed among injecting drug users in Manipur, Mizoram 
and Nagaland - three north-eastern states of India bordering 
Myanmar (Burma). At the beginning of the 1990s, as 
infection rates continued to rise, responses were 
proportionately strengthened. In 1992, the Government of 
India set up the National AIDS Control Organisation 
(NACO), to oversee the formulation of policies, prevention 
work and control programmes relating to HIV and AIDS [2]. 
In the same year, the Government of India launched a 
Strategic Plan for HIV prevention. This plan established the 
administrative and technical basis for programme 
management and also set up State AIDS bodies in 25 states 
and 7 union territories [3]. It was able to make a number of 
important improvements in HIV prevention such as 
improving blood safety etc. [3]. 42    The Open AIDS Journal, 2010, Volume 4  Satyanarayana and Srivastava 
  It is now clear that although individual states and cities in 
India had separate epidemics, HIV had spread to the general 
population by the 1990s. Currently, the epidemic affects all 
sectors of Indian society, even those initially considered not 
at risk [4]. 
TREATMENT FOR PEOPLE LIVING WITH HIV 
  Antiretroviral drugs (ARVs), which can significantly 
delay the progression from HIV to AIDS – have been 
available in developed countries since 1996 [5]. There are 
currently over 30 ARVs available globally [6]. These include 
largely NRTIs, NNRTIs, Protease inhibitors, the new Fusion 
inhibitors, Entry inhibitors-CCR5 co-receptor antagonists 
and HIV integrase strand transfer inhibitors – both single 
drugs and fixed dose combinations (FDCs) (Table 1). The 
major originator companies include: Abbott, Boehringer 
Ingelheim (BI), Bristol-Myers Squibb (BMS), Gilead, 
GlaxoSmithKline (GSK), Merck, Pfizer, Roche, and Tibotec 
Table 1.  Total Antiretroviral Drugs Available 
 
Drug 
S. No.  Class 
Brand Name  Active Ingredient 
Company  Year of 
Approval  Remarks 
1 NRTI  Retrovir  Zidovudine  (AZT)  GSK  1987   
2 NRTI  Epivir  Lamivudine  (3TC)  GSK  1995   
3 NRTI  Zerit  Stavudine  (d4T)  BMS  1994   
4 NRTI  Videx  Didanosine  (ddl)  BMS  1989   
5  NRTI  Videx EC  enteric coated didanosine (ddI EC)   BMS  2000   
6 NRTI  Ziagen  Abacavir  (ABC)  GSK  1988   
7  NRTI  Viread  Tenovofir Disoproxil Fumarate (TDF)  Gilead  2002   
8 NRTI  Emtriva  Emtricitabine  (FTC)  Gilead  2003   
9 NRTI  Trizivir  abacavir, zidovudine, and lamivudine 
(ABC, AZT and 3TC)  GSK 2000  3NRTI 
10  NRTI  Combivir  lamivudine and zidovudine (3TC and AZT)  GSK  1997  2 NRTI 
11  NRTI  Epzicom  abacavir and lamivudine (ABC and 3TC)  GSK  2004  2 NRTI 
12 NRTI  Truvada  tenofovir disoproxil fumarate and 
emtricitabine (TDF and FTC) 
Gilead 2004  2  NRTI 
13 NNRTI  Viramune  Nevirapine  (NVP)  BI  1996   
14 NNRTI  Sustiva  Efavirenz  (EFV)  BMS  1998   
15 NNRTI  Rescriptor  Delavirdine  (DLV)   Agouron  2003   
16  NNRTI  Intelence   Etravirine   Tibotec  2008   
17 NNRTI+NRTI  Atripla  efavirenz, emtricitabine and tenofovir 
disoproxil fumarate (EFV, FTC and TDF) 
Gilead 2006  NNRTI+NRTI 
combination  
18 PI  Crixivan  Indinavir  (IDV)  Merck  1996   
19 PI  Viracept  Nelfinavir  (NFV)  Agouron  1997   
20 PI  Invirase  Saquinavir  (SQV)  Roche  1997  Withdrawn 
2005 
21 PI  Norvir  Ritonavir  (RTV) Abbott  2000   
22 PI  Agenerase Amprenavir  (APV) GSK  1997  Withdrawn 
2007 
23  PI   -  Lopinavir (LPV)   -  2000   
24  PI  Kaletra  Lopinavir (LPV)+Ritonavir (RTV)  Abbott  2005  2 PI 
25 PI  Reyataz  Atazanavir  (ATV) BMS  2003   
26 PI  Lexiva  Foseamprenavir    GSK  2003   
27 PI  Prezista  Darunvir  ethanolate    Tibotec  2006   
28 PI  Aptivus  Tipranavir  (TPV)  BI  2005   
29  Fusion Inhibitor  Fuzeon  Enfuvirtide (T-20)  Roche  2003   
30  Entry Inhibitors-CCR5 co-
receptor antagonist 
Selzentry Maraviroc    Pfizer  2007   
31  HIV integrase strand 
transfer inhibitors  Isentress Raltegravir  Potassium  Merck  2007   
Source: 
1.  HIV prevelance data\USFDA Approved HIV AIDS Drug updated 14/05/2009 
2.  Electronic Orange Book updated Feb, 2009 Patent Pooling for Promoting Access to Antiretroviral Drugs in India  The Open AIDS Journal, 2010, Volume 4    43 
[7]. The availability of ARV drugs began in 1987 with the 
zidovidine and the latest ones to be approved in 2007 are the 
Maraviroc [8] and Raltegravir [9]  potassium marketed as 
Selzentry (Pfizer) and Isentress (Merck) respectively. 
  There are about 30 ARV drugs available in India (Table 
2). Data show that almost all classes of drugs are 
manufactured and sold by the generic manufacturers viz., 
Aurobindo, Hyderabad, Andhra Pradesh; Cipla Limited, 
Verna Industrial Estate, Goa; Emcure Pharmaceuticals, Pune, 
Maharashtra; Hetero Drugs, Hyderabad, Andhra Pradesh; 
Macleods Pharmaceuticals, Kachigam, Daman; Matrix 
Laboratories, Nashik, Maharashtra; Ranbaxy, Sirmour, 
Himachal Pradesh; and Strides Arcolab, Anekal Taluk, 
Bangalore. 
  The drugs available in India thus include both single drug 
and FDCs covering both the first line and second line ARVs 
[10-12]. The Government of India launched the free 
antiretroviral treatment (ART) programme in 2004, starting 
with eight tertiary-level government hospitals in the six high-
prevalence states of India [3]. All persons with HIV infection 
who are clinically eligible to receive ART are included in the 
Phase I of the programme. The subgroups of the people 
living with HIV/AIDS (PLHA) targeted on a priority basis 
include: (i) sero-positive mothers who have participated in 
the prevention of parent-to-child transmission (PPTCT) 
programme; (ii) sero-positive children below the age of 15 
years; and (iii) people with AIDS who seek treatment in 
government hospitals [3]. The free ART programme 
envisages a comprehensive prevention, care and treatment 
programme, with i) standardized, simplified combination of 
ART regimens; ii) regular secure supply of good-quality 
ARV drugs; and iii) a robust monitoring and evaluation 
system eventually working towards universal access to care 
and treatment [3]. 
  Linkages and referrals to other programmes as the 
prevention of parent-to-child transmission (PPTCT), 
programme are also being strengthened to enable women and 
children living with HIV/AIDS have greater access to 
treatment. The Phase I programme is also establishing 
linkages with other related national programmes as the 
Revised National Tuberculosis Control Programme 
(RNTCP), Reproductive and Child Health (RCH) 
Programme and the massive National Rural Health Mission 
(NRHM) [3]. 
ACCESS TO ARVs IN INDIA 
  Currently there are over 160 ART ARV centers in 31 
States and Union Territories [6] with an estimated 140,000 
patients are receiving ARVs free of cost at these centers [13]. 
Another 35,000 patients are receiving free ARVs at ART 
centers run by NGOs and other organizations [3]. The ART 
centres are being scaled up in a phased manner to provide 
free ARVs to 100,000 patients by the end of 2007 and 
300,000 patients by 2011 in 250 centres across India under 
phase III of NACO [13]. ARV drugs including combination 
containing ingredients for adults are: i) Two drug 
combination tablets containing Stavudine and Lamivudine;  
 
ii) Two drugs combination tablets containing Zidovudine 
and Lamivudine; iii) Three drugs combination tablets 
containing Stavudine, Lamivudine and Nevirapine; iv) Three 
drug combination tablets containing Zidovudine, 
Lamivudine and Nevirapine; v) Efavirenz [3]. The following 
drugs are used for pediatric HIV management for children 
weighing up to 20 kg: FDCs i) Stavudine and Lamivudine; 
ii) Stavudine and Lamivudine; iii) Stavudine, Lamivudine 
and Nevarapine; iv) Stavudine, Lamivudine and Nevarapine; 
and v) Efavirenz [4]. But some drugs are still not available in 
India as single drugs, as per our analysis (Table 3). These 
include four protease inhibitors (Agenerase, Aptivus, Lexiva, 
and Prezista), one NNRTI (Rescriptor) and one Fusion 
inhibitor (Fuzeon) [7, 14]. 
  Thus, only about 150,000 people with HIV/AIDS access 
the ARVs from the public sector while some also get these 
through private health facilities, which dominate India’s 
healthcare sector. But the vast majority of 2.4 million PLHA 
cannot afford to buy treatment privately. While the coverage 
of treatment continues to remain unacceptably low, 
improvements are being made to expand access to ARVs in a 
number of areas [15]. This is a massive challenge for the 
NACO, Govt. of India. 
  The HIV/AIDS is a chronic disease requiring lifelong 
treatment with different ARV combinations compounding 
the problem for people who also develop drug resistance and 
side effects over time [16]. Thus, increasing access to ARVs 
also means that an increasing number of people living with 
HIV in India are likely to develop resistance to the first line 
treatment necessitating switching over to the second line 
ARVs. Data from Africa show that over a five year period 
22% people needed such a switch-over [16]. In addition, 
another study from South Africa found that within 3 years on 
ART, 21% of patients who had started a d4T-based regimen 
needed to be switched because of toxicity [17]. This resulted 
in a 2006 recommendation by the WHO to move away from 
d4T to less toxic combinations based on either AZT or 
tenofovir [18], of course with a significant price 
implications. In 2008, the NACO began to roll out 
government funded second-line anti-retroviral treatment in 
two centres in Mumbai and Chennai [6]. There are also plans 
to improve the provision of nevirapine to pregnant mothers 
with HIV, which can significantly reduce the risk that they 
will pass infection on to their child [6]. In common with 
other parts of the developing world, the second line ARV 
treatment in India is currently prohibitively more expensive 
than the first line treatment which is essentially based on the 
generics. 
  Despite several global initiatives to provide ARV 
treatment in poor and middle income countries, like the 3 by 
5 and the current efforts towards Universal Access, the 
outreach is still poor with the targets well behind with 
coverage of an estimated 3 million or about 31% of the 9.7 
million needing the ARVs [15, 16]. What is more, about 2.5 
million new infections were added during 2007 underscoring 
the massive task ahead. Another matter of serious concern is 
the estimated 2.1 million children under 15 years needing  
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Table 2.  Antiretroviral Drugs Available in India 
 
S. No.  Class  Drug  
(Active Ingredient)  Company Remarks   
1 NRTI  Zidovudine  (AZT)* 
Ranbaxy (Sirmour, Himachal Pradesh), Aurobindo (Hyderabad, 
Andhra Pradesh), Cipla (Verna Industrial Estate, Goa), Matrix 
Laboratories (Nashik, Maharashtra), Hetero Drugs (Hyderabad, 
Andhra Pradesh)  
Second Line 
2  NRTI  Lamivudine (3TC) # 
Ranbaxy (Sirmour, Himachal Pradesh), Cipla Limited (Verna 
Industrial Estate, Goa), Matrix Laboratories (Nashik, 
Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh), 
Macleods Pharmaceuticals (Kachigam, 
Daman) 
Second Line 
3 NRTI Stavudin  (d4T)* 
Aurobindo (Hyderabad, Andhra Pradesh), Matrix Laboratories 
(Nashik, Maharashtra), Cipla (Verna Industrial Estate, Goa), 
Emcure Pharmaceuticals (Pune, Maharashtra), Hetero Drugs 
(Hyderabad, Andhra Pradesh)  
- 
4  NRTI  Didanosine (ddl)*  Aurobindo (Hyderabad, Andhra Pradesh)  Second Line 
5 NRTI Abacavir sulfate 
(ABC) # 
Aurobindo (Hyderabad, Andhra Pradesh), Matrix Laboratories 
(Nashik, Maharashtra)  Second Line 
6  NRTI  Emtricitabine (FTC) #  Aurbindo (Hyderabad, Andhra Pradesh), Matrix Laboratories 
(Nashik, Maharashtra)  - 
7 NRTI  Tenofovir disoproxil 
fumarate (TDF) #  Matrix Laboratories (Nashik, Maharashtra)  Second Line 
8 NRTI 
Abacavir, zidovudine, 
and lamivudine 
(ABC, AZT and 3TC) 
# 
Aurbindo (Hyderabad, Andhra Pradesh) 
3NRTI; Trizivir US brand 
name in Indian generic 
FDC manufactured; First 
Line 
9 NRTI 
Lamivudine and 
zidovudine (3TC and 
AZT) # 
Aurobindo (Hyderabad, Andhra Pradesh), Pharmacare Ltd, Cipla 
(Verna Industrial Estate, Goa), Emcure Pharmaceuticals Limited 
(Pune, Maharashtra), Matrix Laboratories (Nashik, Maharashtra), 
Hetero Drugs (Hyderabad, Andhra Pradesh)  
2 NRTI; Combivir US 
brand name in Indian 
generic FDC manufactured; 
First Line 
10 NRTI 
Abacavir and 
lamivudine (ABC and 
3TC) # 
Aurobindo (Hyderabad, Andhra Pradesh) 
2 NRTI; Epzicom US 
brand name in Indian 
generic FDC manufactured 
11 NRTI 
Tenofovir disoproxil 
fumarate and 
emtricitabine (TDF 
and FTC) # 
Matrix Laboratories (Nashik, Maharashtra), Aurobindo 
(Hyderabad, Andhra Pradesh) 
2 NRTI; Truvada US brand 
name in Indian generic 
FDC manufactured; Second 
Line 
12 2  NRTI 
Lamivudine+Tenofov
ir Disoproxil 
Fumarate # 
Matrix Laboratories (Nashik, Maharashtra)  - 
13 2  NRTI 
Abacavir 
Sulfate+Lamivudine 
# 
Aurobindo (Hyderabad, Andhra Pradesh)   
14 3  NRTI 
Lamivudine+Zidovud
ine+Abacavir Sulfate 
# 
Aurbindo (Hyderabad, Andhra Pradesh)  First Line 
15 NNRTI  Nevirapine  (NVP)  # 
Ranbaxy (Sirmour, Himachal Pradesh), Aurobindo (Hyderabad, 
Andhra Pradesh), Cipla (Verna Industrial Estate, Goa), Strides 
Arcolabs (Anekal Taluk Bangalore), Hetero Drugs (Hyderabad, 
Andhra Pradesh), Matrix Laboratories (Nashik, Maharashtra) 
First Line 
16 NNRTI  Efavirenz  (EFV)  # 
Aurobindo (Hyderabad, Andhra Pradesh), Cipla Limited (Verna 
Industrial Estate, Goa), Strides Arcolab (Anekal Taluk 
Bangalore), Matrix Laboratories (Nashik, Maharashtra), Emcure 
Pharmaceuticals (Pune, Maharashtra), Hetero Drugs (Hyderabad, 
Andhra Pradesh)  
First Line 
17  NNRTI  Etravirine #  Johnson & Johnson  
204028; mail-box 
application no. 
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treatment while the coverage is about 10% only [15]. 
Funding for the purchase of the drugs remains a serious 
constraint with the gap between required and available 
resources of US$8.1 billion during 2007. To meet the 
universal targets, funding needs to be enhanced to at least 
four times to US$ 35 billion in 2010 and to US$41 billion in 
2015 [15]. One critical factor continues to be the cost of 
ARVs [15]. 
IMPACT OF NEW PATENT REGIMES 
  In the light of the new TRIPS-complaint IP regime [19] 
in India and other developing countries and the need to find 
(Table 2) contd….. 
S. No.  Class  Drug  
(Active Ingredient)  Company Remarks   
18 NNRTI+NRTI 
Efavirenz, 
emtricitabine and 
tenofovir disoproxil 
fumarate (EFV, FTC 
and TDF) 
Viraday is manufactured by Cipla 
NNRTI+NRTI 
combination; Atripla  
US brand name in  
Indian generic FDC  
called viraday [2] 
19 2  NRTI+NNRTI  Stavudine+Lamivudi
ne+Efavirenz #  Strides Arcolab (Anekal Taluk Bangalore)  First Line 
20 2  NRTI+NNRTI  Lamivudine+Zidovud
ine+Efavirenz # 
Strides Arcolab (Anekal Taluk Bangalore), Aurobindo 
(Hyderabad, Andhra Pradesh)  First Line 
21 2  NRTI+NNRTI  Lamivudine+Zidovud
ine+Nevirapine # 
Aurobindo (Hyderabad, Andhra Pradesh), Cipla Limited (Verna 
Industrial Estate, Goa), Strides Arcolab (Anekal Taluk 
Bangalore) 
First Line 
22 2  NRTI+NNRTI  Lamivudine+Stavudi
ne+Nevirapine #  Strides Arcolab (Anekal Taluk Bangalore)  First Line 
23  PI  Indinavir (IDV) # 
Cipla (Verna Industrial Estate, Goa), Emcure (Pune, 
Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh), 
Ranbaxy (Sirmour, Himachal Pradesh) 
Second Line 
24 PI  Nelfinavir  (NFV)  # 
Cipla (Verna Industrial Estate, Goa), Hetero Drugs (Hyderabad, 
Andhra Pradesh), Macleods Pharmaceuticals (Kachigam, 
Daman) 
Second Line 
25  PI  Ritonavir (RTV) #  Cipla (Verna Industrial Estate, Goa), Hetero Drugs (Hyderabad, 
Andhra Pradesh)   Second Line 
26 PI  Lopinavir/Ritonavir  # 
Matrix Laboratories (Nashik, Maharashtra), Aurobindo 
(Hyderabad, Andhra Pradesh), Cipla (Verna Industrial Estate, 
Goa) 
Second Line 
27  PI  Atazanavir (ATV) #  Emcure Pharmaceuticals (Pune, Maharashtra) 
Second Line 
 
28  PI  Darunavir**  Emcure Pharmaceuticals (Pune, Maharashtra)  Second Line 
28  Fusion Inhibitor   Nil    Nil 
29 
Entry Inhibitors-
CCR5 co-receptor 
antagonist 
Maraviroc  
Patent granted in 
India;204132; mail-box 
Application No. 
885/BOM/1999; Drug 
registration in process [1]
 
Second Line 
30 
HIV integrase 
strand transfer 
inhibitors 
Reltegravir Potassium   
Patent granted in India; 
212400; mail-box 
application no. 
868/CHENP/2004 
Approved Drugs; # Tentatively Approved. 
** Registration pending with the Indian Drug Controller. 
Explanation for classifying drugs (active ingredient) as First Line & Second Line 
single drug- First Line- National AIDS Control Organization (NACO); National Program. 
single drug- Second Line- Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: A Public Health Approach. 
FDC- First Line- NACO+WHO guidelines. 
FDC- Second Line- WHO guidelines. 
Source: 
1. www.jipmer.edu/charu/v4issue1.pdf 
2. http://pharmacy.around-world.biz/drugs/Atripla.html 
3.  USFDA: HIV prevalence data\President's Emergency Plan for AIDS Relief updated 14/05/2009. 
4. Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: a Public Health Approach (First & Second Line). 46    The Open AIDS Journal, 2010, Volume 4  Satyanarayana and Srivastava 
innovative strategies to provide ARVs, there is a need to 
have a serious look at whether the strong IP protection 
system is a barrier. We therefore looked at the patent profile 
of ARV drugs both in India and the USPTO filed by the 
originator companies. Table 4 shows data on the patent 
profile of FDA approved ARVs. We could track 93 patents 
on ARVs filed in the USPTO by the originator companies. 
The major patent filers were Abbot, Gilead, Abbott, GSK 
etc. with the number of patents filed varying with the drug. 
For example, Abbott filed as many as 20 patents on 
Lopinavir-Ritonavir (sold as Kaletra). For combinations as 
Atripla (Efavirenz and Emtricitabine and Tenofovir 
Disoproxil fumerate), Gilead filed as many as 15 patents. 
Similarly, Gilead also filed 10 patents on Truvada 
(Emtricitabine and Tenofovir Disoproxil fumarate). Data on 
break-up of the patents filed at the USPTO show that Gilead 
holds the maximum (25) patents followed by Abbott with 20, 
GSK with 17, Tibotec 5 etc., (Table 5). 
  Significantly, most generic antiretroviral agents currently 
now being used in Africa and Asia are manufactured in India 
as the Indian Patent Act (1970) permitted making generic 
copies of drugs in India [20]. With the largest global 
standard facilities for manufacturing outside the USA, the 
Indian companies were able to offer HIV drugs at a fraction 
of the cost of brand-name drugs. The new Indian patent Act 
(2005) has already created significant barriers for the 
development of new generics on ARVs patented in India 
after 2005 [21]. Developing countries had to allow inventors 
to file patent applications from January 1, 1995, and the 
decision on whether or not to grant any patent could be taken 
at the end of the transition period. This has potentially 
serious impact on global initiatives of MSF, PEPFAR, 
Clinton Foundation etc which source drugs from the Indian 
companies for distribution in African countries [20]. 
  There are also apprehensions that the first-line 
antiretroviral drug regimens in wide use may soon be found 
wanting to meet the needs of HIV-infected patients [22]. 
There is also evidence to show that some people may be   
 
intolerant to some drugs as also reports of contraindications 
that need attention [18, 23]. More importantly, there could be 
treatment failure necessitating drugs outside the available 
ARV drug regimens. In addition, without strong second-line 
therapeutic regimens HIV patients could well stand to lose 
the benefits of antiretroviral therapy. Worse still, they may 
transmit the drug-resistant virus to others compounding the 
problem. "Sustaining" may well soon surpass with "scaling 
up" of antiretroviral therapy emerging as the major challenge 
[22]. Brazil is already facing this challenge, and African and 
Asian countries with far fewer resources will probably 
encounter even greater hurdles in gaining access to second-
line therapies [22]. 
  The impact of Trade Related Aspects of Intellectual 
Property Rights (TRIPs)-complaint legislation [19, 21] on 
access to ARVs to HIV-infected persons in resource-limited 
countries therefore cannot be overemphasized. There is a 
need to find solutions and find them fast. A dual approach 
may be required i) ensure the continued availability of high 
quality generics by manufacturers from India and elsewhere; 
and ii) encourage strong efforts towards developing new 
generics from patented drugs and new formulations through 
newer global strategies. For example, the US FDA has 
approved, under PEPFAR, several generic antiretroviral 
preparations for purchase and use outside the United States 
[10]. 
  There have been a few attempts by the originator 
companies, under intense criticism on their pricing policies, 
to license the ARV drugs. Table 6 shows data on licensing of 
ARV drugs by the originator companies to non-US 
companies, mostly in South Africa, other African countries 
and India. GSK has licensed to maximum companies outside 
the US – 4 companies in the African continent. The BMS has 
licensed its drugs stavudine and didanosine to over 49 
countries including India. Some companies like Gilead have 
licensed manufacture of its drugs to a large number of 
generic companies in India through non-exclusive licensing 
[24]. 
 
Table 3.  ART Drugs Not Available in India as Single Drug 
 
S. No.  Brand 
Name 
Class  Generic  Company 
Manufacturing  
Applicant  Assignee 
1  Rescriptor  NNRTI  Delavirdine (DLV)  Agouron (USA)  Pfizer (USA)  Pharmacia & Upjohn Co 
2  Agenerase  PI  Amprenavir (APV)  GSK (UK)  GSK (UK)  Vertex Pharma GSK 
3  Aptivus  PI  Tipranavir (TPV)   BI (Germany)  BI (Germany)  Pharmacia and  
Upjohn Co. 
4  Lexiva  PI  Fosamprenavir Calcium (FOS-APV)   GSK (UK)  GSK (UK)  Vertex Pharmaceuticals 
5  Prezista*  PI  Darunavir Ethanolate   Tibotec (USA),   Tibotec (USA)  Tibotec (USA) 
6  Fuzeon  Fusion Inhibitor  Enfuvirtide (T-20)   Roche (Switzerland) 
 Roche 
(Switzerland) 
& Trimeris 
Duke University 
Trimeris Inc. 
Source: 
1.  HIV prevalence data/USFDA Approved HIV AIDS Drug Updated January 2008. 
2.  Electronic Orange Book. 
3.  United States Patent & Trade Mark Office. 
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Table 4.  Patent Profile of FDA Approved Drugs 
 
S. No.  U.S. 
Patent No.  Active Ingredient  Proprietary  Applicant  Class  Year of 
Filing 
Patent 
Expiration 
1 5585397  Amprenavir    Agenerase    GSK  PI  24-Nov-93  17-Dec-2013 
2 5646180  Amprenavir    Agenerase    GSK  PI  5-Dec-95 8-Jul-2014 
3 5723490  Amprenavir    Agenerase    GSK  PI  19-Apr-95  3-Mar-2015 
4 6730679  Amprenavir    Agenerase    GSK  PI  20-Mar-97  11-Nov-2017 
5  6436989  Fosamprenavir Calcium   Lexiva   GSK  PI  24-Dec-97  24-Dec-2017 
6  6514953  Fosamprenavir Calcium   Lexiva   GSK  PI  20-Apr-01  15-Jul-2019 
7 5849911  Atazanavir  Sulfate  Reyataz    BMS  PI  9-Apr-97  20-Jun-2017 
8 6087383  Atazanavir  Sulfate  Reyataz    BMS  PI  21-Dec-98  21-Dec-2018 
9  5843946  Darunavir Ethanolate   Prezista   Tibotec   PI  24-Aug-93  1-Dec-2015 
10  6248775  Darunavir Ethanolate   Prezista   Tibotec   PI  8-Apr-99  13-Aug-2014 
11  6335460  Darunavir Ethanolate   Prezista   Tibotec   PI  22-Feb-00  25-Aug-2012 
12  5413999  Indinavir Sulfate   Crixivan   Merck   PI  7-May-93  9-May-2012 
13  6645961  Indinavir Sulfate   Crixivan   Merck   PI  4-Mar-98  4-Mar-2018 
14  5541206  Lopinavir; Ritonavir   Kaletra  Abbott   PI  25-Apr-95  30-Jul-2013 
15  5635523  Lopinavir; Ritonavir   Kaletra  Abbott   PI  6-Apr-95  3-Jun-2014 
16  5648497  Lopinavir; Ritonavir   Kaletra  Abbott   PI  24-Mar-95  15-Jul-2014 
17  5674882  Lopinavir; Ritonavir   Kaletra  Abbott   PI  29-Mar-95  7-Oct-2014 
18  5846987  Lopinavir; Ritonavir   Kaletra  Abbott   PI  20-Mar-97  29-Dec-2012 
19  5886036  Lopinavir; Ritonavir   Kaletra  Abbott   PI  20-Mar-97  19-Nov-2013 
20  5914332  Lopinavir; Ritonavir   Kaletra  Abbott   PI  21-Nov-96  13-Dec-2015 
21  5948436  Lopinavir; Ritonavir   Kaletra  Abbott   PI  13-Mar-95  13-Sep-2013 
22  6037157  Lopinavir; Ritonavir   Kaletra  Abbott   PI  26-Jun-96  26-Jun-2016 
23  6232333  Lopinavir; Ritonavir   Kaletra  Abbott   PI  7-Nov-97  7-Nov-2017 
24  6284767  Lopinavir; Ritonavir   Kaletra  Abbott   PI  8-Dec-98  15-Feb-2016 
25  6458818  Lopinavir; Ritonavir   Kaletra  Abbott   PI  2-Jul-99  7-Nov-2017 
26  6521651  Lopinavir; Ritonavir   Kaletra  Abbott   PI  10-Sep-99  7-Nov-2017 
27  6703403  Lopinavir; Ritonavir   Kaletra  Abbott   PI  20-Sep-01  26-Jun-2016 
28  7141593  Lopinavir; Ritonavir   Kaletra  Abbott   PI  22-May-00  22-May-2020 
29  7432294  Lopinavir; Ritonavir   Kaletra  Abbott   PI  12-Oct-06  22-May-2020 
30  6911214  Lopinavir; Ritonavir   Kaletra  Abbott   PI  4-Sep-01  28-Nov-2021 
31  5484801  Lopinavir; Ritonavir   Kaletra  Abbott   PI  12-May-95  28-Jan-2014 
32  7148359  Lopinavir; Ritonavir   Kaletra   Abbott   PI  4-May-05  19-Jul-2019 
33  7364752  Lopinavir; Ritonavir   Kaletra   Abbott   PI  10-Nov-00  10-Nov-2020 
34  5484926  Nelfinavir Mesylate   Viracept   Agouron   PI  2-Feb-94  7-Oct-2013 
35  5952343  Nelfinavir Mesylate   Viracept   Agouron   PI  7-Jun-95  7-Oct-2013 
36  6162812  Nelfinavir Mesylate   Viracept   Agouron   PI  1-Apr-99  7-Oct-2013 
37 5196438  Saquinavir  Mesylate  Invirase    Roche  PI  19-Nov-90  19-Nov-2010 
38 5852195  Tipranavir  Aptivus    BI  PI  4-Nov-96  22-Jun-2019 
39  6147095 Tipranavir  Aptivus    BI  PI 29-Oct-99  29-Oct-2019 
40 6169181  Tipranavir  Aptivus    BI  PI  9-Nov-98  6-May-2014 48    The Open AIDS Journal, 2010, Volume 4  Satyanarayana and Srivastava 
   
(Table 4) contd….. 
S. No.  U.S. 
Patent No.  Active Ingredient  Proprietary  Applicant  Class  Year of 
Filing 
Patent 
Expiration 
41 6231887  Tipranavir  Aptivus    BI  PI  27-Jul-98 27-Jul-2018 
42 5034394  Abacavir  Sulfate    Ziagen  GSK  NRTIs  22-Dec-89  18-Dec-2011 
43  5089500  Abacavir Sulfate   Ziagen   GSK  NRTIs  8-May-91  26-Jun-2009 
44  6294540  Abacavir Sulfate   Ziagen   GSK  NRTIs  1-Dec-99  14-May-2018 
45  6641843  Abacavir Sulfate   Ziagen   GSK  NRTIs  4-Aug-00  4-Feb-2020 
46 5047407 Abacavir  Sulfate;  Lamivudine  Epzicom    GSK  NRTIs  8-Feb-89  17-Nov-2009 
47 5905082 Abacavir  Sulfate;  Lamivudine  Epzicom    GSK  NRTIs  2-Jun-92  18-May-2016 
48 6417191 Abacavir  Sulfate;  Lamivudine  Epzicom    GSK  NRTIs  30-Sep-97  28-Mar-2016 
49 7119202 Abacavir  Sulfate;  Lamivudine  Epzicom    GSK  NRTIs  6-Jun-95 8-Feb-2009 
50 6004968  Lamivudine    Epivir    GSK  NRTIs  20-Mar-98  20-Mar-2018 
51 RE39155  Lamivudine    Epivir-Hbv  GSK  NRTIs  23-Jul-92 2-Jul-2013 
52 5859021  Lamivudine;  Zidovudine  Combivir  GSK  NRTIs  22-Feb-96  15-May-2012 
53 5210085  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  22-Feb-91  11-May-2010 
54 5519021  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  2-Jun-95  21-May-2013 
55 5663169  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  2-Jun-95  2-Sep-2014 
56 5811423  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  12-Mar-97  7-Aug-2012 
57 5814639  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  16-Feb-93  29-Sep-2015 
58 5914331  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  7-Jun-95  2-Jul-2017 
59 5922695  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  25-Jul-97  25-Jul-2017 
60 5935946  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  25-Jul-97  25-Jul-2017 
61 5977089  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  6-Nov-98  25-Jul-2017 
62 6043230  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  19-May-99  25-Jul-2017 
63 6639071  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  19-Oct-01  14-Feb-2018 
64 6642245  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  7-Jun-95  4-Nov-2020 
65 6703396  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  7-Jun-95  9-Mar-2021 
66 6939964  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  24-Jun-04  20-Jan-2018 
67 7402588  Efavirenz; Emtricitabine; 
Tenofovir Disoproxil Fumarate   Atripla   Gilead   NRTIs  28-Mar-06  1-Feb-2010 
68 5210085  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  22-Feb-91  11-May-10 
69 5814639  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  16-Feb-93  29-Sep-15 
70 5914331  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  7-Jun-95  2-Jul-17 Patent Pooling for Promoting Access to Antiretroviral Drugs in India  The Open AIDS Journal, 2010, Volume 4    49 
 
OPTIONS TO PROMOTE ACCESS TO NEWER ARVs 
  A priority now is to, among others, find less toxic first-
line ARV combinations and drug options when resistance is 
developed [23]. The primary issue continues to be strong 
TRIPS-complaint global patenting regimes which impact the 
key generics-producing countries such as India, Brazil, and 
Thailand. The MSF estimates that the ARV prices are 
unlikely to see the dramatic 99% drop seen for the currently 
used first-line ARVs - from >$10,000 per patient per year in 
2000 to $87 today [16]. National Governments of developing 
countries will therefore have difficult choices before them 
like whether to treat more number of patients on more 
affordable ARV combinations, or fewer people on less toxic 
but more expensive combinations. 
  Simple switching over from the most commonly used 
d4T-based first-line ARV combination to a less toxic option 
involves about twice the cost [23]. And changing over to a 
TDF-based ARV regimen would mean a 4-11 fold price 
increase [23]. According to MSF’s estimates, replacing d4T 
with a TDF-based regimen for all patients from 2008 to 2014 
(Table 4) contd….. 
S. No.  U.S. 
Patent No.  Active Ingredient  Proprietary  Applicant  Class  Year of 
Filing 
Patent 
Expiration 
71 5922695  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  25-Jul-97  25-Jul-17 
72 5935946  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  25-Jul-97  25-Jul-17 
73 5977089  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  6-Nov-98  25-Jul-17 
74 6043230  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  19-May-99  25-Jul-17 
75 6642245  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  7-Jun-95  4-Nov-20 
76 6703396  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  13-Mar-95  9-Mar-21 
77 7402588  Emtricitabine; Tenofovir 
Disoproxil Fumarate  Truvada   Gilead   NRTIs  28-Mar-06  1-Feb-10 
78  5563142  Delavirdine Mesylate  Rescriptor   Agouron   NNRTIs  22-Feb-94  8-Oct-2013 
79  6177101  Delavirdine Mesylate  Rescriptor   Agouron   NNRTIs  7-Jun-99  7-Jun-2019 
80  6238695  Efavirenz   Sustiva   BMS  NNRTIs  6-Apr-99  6-Apr-2019 
81  6555133  Efavirenz   Sustiva   BMS  NNRTIs  2-Apr-01  6-Apr-2019 
82  6878717  Etravirine   Intelence   Tibotec   NNRTIs  1-Nov-99  5-Nov-2019 
83  7037917  Etravirine   Intelence   Tibotec   NNRTIs  5-Aug-03  5-Nov-2019 
84  5366972  Nevirapine   Viramune   BI   NNRTIs  13-Jul-93  22-Nov-2011 
85  5464933  Enfuvirtide  Fuzeon   Roche  Fusion Inhibitor  7-Jun-93  7-Jun-2013 
86  6133418  Enfuvirtide  Fuzeon   Roche  Fusion Inhibitor  6-Nov-95  17-Nov-2014 
87  6475491  Enfuvirtide  Fuzeon   Roche  Fusion Inhibitor  19-Dec-96  7-Jun-2015 
88 6586430  Maraviroc  Selzentry    Pfizer    Entry Inhibitors-CCR5 co-
receptor antagonist  1-Dec-99 1-Dec-2019 
89 6667314  Maraviroc  Selzentry    Pfizer    Entry Inhibitors-CCR5 co-
receptor antagonist  25-May-01 25-May-2021 
90 7368460  Maraviroc  Selzentry    Pfizer    Entry Inhibitors-CCR5 co-
receptor antagonist  3-Oct-03 25-Nov-2022 
91  7169780  Raltegravir Potassium   Isentress   Merck   HIV integrase strand 
transfer inhibitors  1-May-03 9-Oct-2023 
92  7217713  Raltegravir Potassium   Isentress   Merck   HIV integrase strand 
transfer inhibitors  24-Jul-06 21-Oct-2022 
93  7435734  Raltegravir Potassium   Isentress   Merck   HIV integrase strand 
transfer inhibitors  19-Dec-06 21-Oct-2022 
Souce:  
Electronic Orange Book updated Feb, 2009. 50    The Open AIDS Journal, 2010, Volume 4  Satyanarayana and Srivastava 
(based on today’s prices) would mean a 4-11 fold price 
increase [16, 25]. Unless there are overall price reductions the 
overall increase of cost for ARVs. in some middle-income 
countries could be as high as 17-fold [16]. 
  Besides the availability of generics for the first-line 
ARVs in countries with manufacturing capacity like India, 
Brazil, and Thailand, multiple producers and the resultant 
competition has actually brought down prices dramatically 
[16]. Globally, India is considered the “pharmacy of the 
developing world,” as charities like MSF source over 80% of 
its ARVs from India as also other ARV providers like the 
Clinton Foundation, PEPFAR etc.  [16, 20]. This was 
possible only because the pre-TRIPS patent regimes allowed 
the development of single drugs and FDCs, an innovation 
that not just simplified HIV/AIDS treatment but helped 
significant scale-ups. In the recent years, there have been 
aggressive patenting by originator companies in countries 
like India, Brazil and Thailand [26-28]. 
  The global battle for affordable ARVs, thus is likely to 
get tougher in future. Developing countries with significant 
PLHA need to use all the means available including public 
health safeguards and flexibilities enshrined in the WTO 
TRIPS as reiterated in the Doha Declaration [29] that allows 
countries to overcome patent barriers by issuing compulsory 
licenses (CLs) to open the market to competition despite 
patent protection. 
  Other options open to sovereign countries include design 
or interpret national patent laws to limit the scope of 
patentability of new chemical entities with a public health 
priority and other strategies [30, 31]. Like, for example, the 
Indian Patents Act (2005) that allows pre-grant opposition 
[32]. In June 2008 such an opposition was successfully 
contested in India for the pediatric syrup formulation of NVP 
as the Indian patent office rejected the patent [26-28]. 
PATENT POOLS 
  In what is considered a path-breaking development, the 
UNITAID decided in principle in July 2008 to establish a 
patent pool for ARVs [33] that may hold the key for access 
to affordable newer ARVs in the future. This concept was 
originally mooted by the MSF, along with Essential 
Inventions to the UNITAID board in June 2006 to overcome 
the difficulties to access newer ARVs. As Ellen t’Hoen of 
Table 5.  Summary of US Patents on FDA Approved ART Drugs Company Wise 
 
S. No.  Company  No. of Patents  Name of the Drug  Class 
1 GSK  4  Agenerase    PI 
2 GSK  2  Lexiva    PI 
3 GSK  4  Ziagen  NRTIs 
4 GSK  4  Epzicom    NRTIs 
5 GSK  2  Epivir    NRTIs 
6 GSK  1  Combivir  NRTIs 
7  BMS 2 Reyataz    PI 
8 BMS  2  Sustiva    NNRTIs 
9 Tibotec    3  Prezista  PI 
10  Tibotec   2  Intelence   NNRTIs 
11  Merck   3  Isentress   HIV integrase strand transfer inhibitors 
12  Merck   2  Crixivan   PI 
13 Abbott    20  Kaletra  PI 
14  Agouron   3  Viracept   PI 
15 Agouron    2  Rescriptor    NNRTIs 
16 Roche  1  Invirase    PI 
17  Roche  3  Fuzeon   Fusion Inhibitor 
18 BI  4  Aptivus    PI 
19 BI  1  Viramune    NNRTIs 
20  Gilead   15  Atripla   NRTIs 
21  Gilead   10  Truvada   NRTIs 
22  Pfizer   3  Selzentry   Entry Inhibitors-CCR5 co-receptor antagonist 
 Total   93 
Souce:  
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the UNITAIDS explains [34]: “A patent pool is a mechanism 
whereby patent owners put their patents in a ‘pool’ and allow 
others who need access to those patents to use them in 
exchange for a royalty payment. Patent pools have, in fact, 
been used to drive forward innovation in many different 
fields of technology, for example in the development of 
recording equipment, where you need multiple patents to be 
able to produce a certain product”. Hoen considers that the 
patent pooling as a strategy will not only help the 
development of new fixed-dose combination drugs that 
combine multiple compounds into one pill, especially for the 
newer drugs and in developing fixed-dose combinations or 
paediatric formulations [34]. 
  The advantages of patent pool appear to be huge. Like, 
for example, the development of pediatric formulations or 
the much-needed FDCs for less toxic first and second-line 
treatments. Patent filed by originator companies on 
individual compounds typically hamper the development of 
FDCs, a barrier that a patent pool would help break. Generic 
versions of new drugs also could be developed quickly 
through the patent pool as the generic companies need not 
wait for the 20-year patent expiration. If the patent pool is 
accessed by multiple companies, the resultant competition 
Table 6.  Data on Drug Licensing of Originator Companies to Non-U.S. Countries 
 
S. No.  Patent 
Holder 
Drug  Non US Companies Licensed  India  
1 GSK  lamivudine, zidovudine and 
lamivudine + zidovudine  
Cipla Medpro - the third largest generic drug 
company in South Africa; Biotech Laboratories - a 
subsidiary of Afrika Biopharma to supply generic 
antiretrovirals to both the public and private sectors 
throughout sub-Saharan Africa; Feza Pharmaceuticals, 
Thembalami Pharmaceuticals and Aspen Pharmacare 
South Africa, and Cosmos Limited in Kenya [1 & 2] 
NIL 
2  Tibotec  darunavir (Prezista)   Aspen Pharmacare, South Africa [3]  Emcure Pharmaceuticals Ltd, India  
3  BMS  atazanavir (Reyataz)   Aspen Pharmacare, South Africa [4]  Emcure Pharmaceuticals Ltd, India  
4  BMS  stavudine and didanosine  Aurobindo Pharma, in 49 countries including South 
Africa [5]  Aurobindo Pharma, India 
5  Gilead  tenofovir DF  Aspen Pharmacare, South Africa [6] 
Emcure Pharmaceuticals Ltd., Hetero 
Drugs Ltd., Strides Arcolab Ltd, Alkem 
Laboratories 
Aurobindo Pharma FDC, JB Chemicals 
& Pharmaceuticals, Matrix, Medchem 
International, Ranbaxy, Shasun 
Chemicals & Drugs 
6 Gilead  tenofovir disoproxil 
fumarate and emtricitabine 
Aspen Pharmacare, South Africa, sold in 95 
developing countries [7 & 8] 
*Licensing information not available; 
Company manufacturing;Matrix 
Laboratories, Aurobindo  
7 Pfizer  delavirdine   not-for-profit group the Concept Foundation and the 
International Dispensary Association, Thailand [9]  NIL 
8  Merck  efavirenz  Aspen Pharmacare, South Africa [10] 
*Licensing information not available; 
Company manufacturing; Aurobindo, 
Cipla Limited, Strides Arcolab, Matrix 
Laboratories, Emcure Pharmaceuticals, 
Hetero Drugs  
9  GSK & 
BI 
lamivudine+ stavudine+ 
nevirapine (Triomune) 
Enaleni Pharmaceuticals, a subsidiary of Indian 
generic drugs manufacturer Cipla, South Africa [11]  NIL 
10  BI  nevirapine  Aspen Pharmacare, South Africa [12] 
*Licensing information not available; 
Company manufacturing; Ranbaxy, 
Aurobindo, Cipla, Strides Arcolabs, 
Hetero Drugs, Matrix Laboratories  
Sources: 
1.  www.thebodypro.com/content/art11014.html - 20k - 
2. http://www.empowermentsa.co.za/betalk.php?myid=27 
3. http://www.tibotec.com/bgdisplay.jhtml?itemname=dw_leftblock1 
4.  www.medicalnewstoday.com/articles/38017.php - 59k 
5.  www.haiafrica.org/index.php?option=com_content&task=view&id=105&Itemid=1 - 31k 
6. http://www.gilead.com/access_partnerships 
7. http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=700521&highlight 
8. http://www.aegis.com/NEWS/BW/2005/BW050411.html 
9. http://www.thebodypro.com/content/art11680.html 
10.  www.medicalnewstoday.com/articles/27787.php - 53k  
11. http://icommons.org/article_print/a-sick-state-access-to-medicine-in-south-africa  
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should drive down the price, as seen for the current first line 
ARVs. What is more, these drugs could be exported to poor 
countries with HIV/AIDS load that have no manufacturing 
capability by countries like India, Brazil and Thailand. All 
these could be built into the licensing agreements with the 
originator companies that own the patents. But this can 
become successful only if the patent owning companies are 
willing to put their patents into the pool. Efforts are on at the 
UNITAID to work out the modalities of operating the 
proposed patent pool. In fact the recently concluded WHO 
Global Strategy and Plan of Action on Public Health, 
Innovation and Intellectual Property of the Inter-
Governmental Working Group on Public Health and 
Innovation [35] had recommended exploring the feasibility 
of patent pools for diseases of the poor [36]. By the end of 
2009, the UNITAID pool is eventually expected to run as a 
separate entity [37]. 
  The need for affordable ARVs to vulnerable sections of 
society like children, pregnant women and people with HIV-
TB in resource-poor countries cannot be overemphasized. 
The urgency is especially for the paediatric populations as, 
of the 22 ARVs approved by the US FDA for adults, as 
many as 8 are not approved for use in children while 9 do 
not have any pediatric formulations [38]. 
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